Search results
Showing 16 to 30 of 353 results for hypertension
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic p...
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development [GID-TA10431] Expected publication date: TBC
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459
In development [GID-TA11572] Expected publication date: TBC
Alcohol use: risk assessment for people with hypertension (IND196)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after the date of entry on the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved
Alcohol use: brief intervention for people with hypertension (IND197)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of 3 or more or AUDIT-C score of 5 or more who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM176
This indicator covers the percentage of patients with hypertension or diabetes and a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been referred to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM203
This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing.
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
This indicator covers the percentage of patients aged 80 years or over with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is less than 145/85 mmHg if using ambulatory or home monitoring, or less than 150/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM224
This indicator covers the percentage of patients aged 79 years or under with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM223
Hypertension in pregnancy: diagnosis and management - Chronic hypertension: pre-pregnancy advice Chronic...
This indicator covers, in patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of more than 20% in the preceding 12 months, the percentage who are currently treated with statins (unless there is a contraindication). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM133
Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)
Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.